Active Ingredient: Buserelin
Buserelin is indicated For the treatment of advanced hormone dependent prostatic carcinoma (stage C or stage D according to the classification of Murphy et al, in Cancer 45, p1889-95, 1980) in which suppression of testosterone is indicated; however, not after bilateral orchiectomy (no further reduction of testosterone level by buserelin to be expected).
Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotropin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
1.5 - 1.5 mg
From 0.5 To 0.5 mg 3 time(s) per day every day for 7 day(s)
Initiation of therapy: is most conveniently carried out in hospital; 0.5mg buserelin injection should be injected subcutaneously at 8 hourly intervals for 7 days.
Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of buserelin.
Nasal
1.2 - 1.2 mg
From 0.2 To 0.2 mg 6 time(s) per day every day
Initiation of therapy: is most conveniently carried out in hospital; 0.5 ml buserelin injection should be injected subcutaneously at 8 hourly intervals for 7 days.
Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of buserelin. One spray dose is introduced into each nostril 6 times a day according to the following schedule:
This dosage regimen is to ensure adequate absorption of the material and to distribute the dose throughout the day.
If used correctly, reliable absorption of the active ingredient takes place via nasal mucous membranes. Buserelin nasal spray is absorbed even if the patient has a cold.
If nasal decongestants are being used concurrently, they should be administered at least 30 minutes after buserelin.
Subcutaneous
9.45 mg
9.45 mg once every 90 day(s)
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
